公开(公告)号：US11828759B2

公开(公告)日：2023-11-28

申请号：US16077025

申请日：2017-02-10

申请人： Peter MacCallum Cancer Institute

发明人： Belinda Sheree Parker ,  Hendrika Martha Duivenvoorden

IPC分类号： G01N31/00 ,  G01N33/53 ,  G01N33/574 ,  C12Q1/6886 ,  C12Q1/68 ,  A61K39/00 ,  A61N5/00

CPC分类号： G01N33/57415 ,  A61K39/0011 ,  A61N5/00 ,  C12Q1/68 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/8139

摘要： The present invention relates generally to a method of detecting a risk of the progression from a pre-invasive neoplasia of the glandular epithelium. More particularly, the present invention provides a method of detecting a risk of the progression from a pre-invasive breast neoplasia by screening for the level of expression of Stefin A in the myoepithelial cells. The method of the present invention is useful in a range of applications including, but not limited to, assessing a neoplastic condition, monitoring the progression of such a condition, predicting the likelihood of a subject progressing to a more advance disease state or informing decisions in relation to the design of treatment schedules.

公开(公告)号：US20230372460A1

公开(公告)日：2023-11-23

申请号：US18081178

申请日：2022-12-14

申请人： LURONG ZHANG

发明人： LURONG ZHANG

IPC分类号： A61K39/00 ,  A61P35/00 ,  C12N5/09 ,  C12N13/00 ,  G01N33/68 ,  G01N33/574

CPC分类号： A61K39/0011 ,  A61P35/00 ,  C12N5/0693 ,  C12N13/00 ,  G01N33/6854 ,  G01N33/57484 ,  C12N2521/00

摘要： The invention relates to induced neoantigen vaccines and a method of using same to treat cancer by enhancing a patient's anti-cancer immunity. The method involves application of an induction radiation to the patient to generate an “in situ vaccine” in vivo, subsequent removal of the tumor, subjecting its cells to a survival pressure for further production of neoantigens in vitro, and processing of the cells to obtain a self-tumor vaccine. The invention provides comprehensive mobilization of individualized anti-cancer active immunity via sequential combination of means of cancer treatments (e.g., radiotherapy, surgery, chemotherapy). Another aspect of the invention relates to an immunoassay protocol to monitor parameters indicative of the cellular and humoral anti-cancer immunity of a patient.

公开(公告)号：US20230365707A1

公开(公告)日：2023-11-16

申请号：US18134844

申请日：2023-04-14

申请人： BioNTech Research and Development, Inc.

发明人： Ritsuko Sawada ,  Shu-Man Sun ,  Wolfgang Scholz

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K51/10 ,  C07K16/30 ,  A61K39/00 ,  A61K31/337 ,  G01N33/574 ,  G01N33/577

CPC分类号： C07K16/2896 ,  C07K16/28 ,  A61K39/39533 ,  A61K45/06 ,  A61K51/1045 ,  A61K51/1057 ,  C07K16/3076 ,  A61K39/0011 ,  A61K31/337 ,  A61K39/39558 ,  A61K51/1027 ,  A61K51/1093 ,  G01N33/57438 ,  G01N33/577 ,  C07K2317/56 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92 ,  A61K2039/6081 ,  C07K2317/626

摘要： The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.

公开(公告)号：US20230364211A1

公开(公告)日：2023-11-16

申请号：US18157534

申请日：2023-01-20

申请人： ISTITUTO SUPERIORE DI SANITÀ

发明人： Maurizio Paolo Maria FEDERICO

IPC分类号： A61K39/00 ,  C12N15/62 ,  A61K9/00

CPC分类号： A61K39/0011 ,  A61K39/001106 ,  A61K39/001186 ,  A61K39/00119 ,  C12N15/62 ,  A61K39/001191 ,  A61K9/0019 ,  A61K2039/572 ,  A61K2039/53

摘要： The present invention concerns a nucleotide sequence expressing a fusion protein, said fusion protein comprising or consisting of an exosome-anchoring protein fused at its C-terminus with an antigen, or a DNA expression vector comprising said nucleotide sequence, for use as vaccine.

公开(公告)号：US11814679B2

公开(公告)日：2023-11-14

申请号：US16061591

申请日：2017-01-10

申请人： Eli Lilly and Company

发明人： John Brian Mumm ,  Ivan Ho Chan ,  Scott McCauley ,  Scott Ogg ,  Martin Oft

IPC分类号： C12N5/00 ,  A61K39/00 ,  C12Q1/6881 ,  A61K38/20 ,  A61K39/39 ,  A61K47/60 ,  A61P35/00 ,  A61K35/17 ,  A61K45/06 ,  C07K14/725 ,  C12N5/0783

CPC分类号： C12Q1/6881 ,  A61K35/17 ,  A61K38/2066 ,  A61K39/0011 ,  A61K39/39 ,  A61K45/06 ,  A61K47/60 ,  A61P35/00 ,  C07K14/7051 ,  C12N5/0637 ,  A61K2039/55527 ,  A61K2039/572 ,  C12N2501/998 ,  C12Q2600/136

摘要： The present disclosure provides methods and compositions relating to isolated CD8+ T cells expressing a disease antigen-specific T cell receptor, as well as nucleic acids encoding the Vα and Vβ polypeptide pairs of T cell receptors (TCRs) of such disease antigen-specific T cells. Such disease antigen-specific CD8+ T cells are obtainable from the periphery (e.g., blood) of a subject having a disease amenable to treatment with an IL-10 agent. The present disclosure also contemplates therapeutic methods and compositions relating to administration of isolated disease antigen-specific CD8+ T cells to a subject, as well as therapeutic methods and compositions relating to CD8+ T cells genetically modified to express a disease antigen-specific TCR and/or chimeric antigen receptor.

公开(公告)号：US11813485B2

公开(公告)日：2023-11-14

申请号：US17161498

申请日：2021-01-28

申请人： The Regents of the University of Michigan ,  The United States Government as represented by the Department of Veterans Affairs

发明人： Zhen Xu ,  Clifford Suhyun Cho

IPC分类号： A61N7/00 ,  A61K39/00 ,  A61B10/00

CPC分类号： A61N7/00 ,  A61K39/0011 ,  A61B10/0045

摘要： Systems and methods for histotripsy and immunotherapy are provided. In some embodiments, histotripsy can be applied to a target tissue volume to lyse and solubilize the target tissue volume to release tumor antigens. In some embodiments, an immune response of the treatment can be evaluated. In other embodiments, an immune therapy can be applied after applying the histotripsy. In one embodiment, the lysed and solubilized cells can be extracted from the tissue. The extracted cells can be used to create immune therapies, including vaccines.

公开(公告)号：US11806391B2

公开(公告)日：2023-11-07

申请号：US17313335

申请日：2021-05-06

申请人： Madison Vaccines Inc.

发明人： Doug McNeel ,  Richard Lesniewski

IPC分类号： A61K39/00 ,  C07K16/28 ,  A61P35/04 ,  A61P35/00 ,  A61K39/395 ,  C07K16/30

CPC分类号： A61K39/001193 ,  A61K39/0011 ,  A61K39/001163 ,  A61K39/3955 ,  A61P35/00 ,  A61P35/04 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/884 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/76

摘要： Provided herein is technology relating to cancer treatment and prevention and particularly, but not exclusively, to compositions and methods related to therapies for prostate cancer.

公开(公告)号：US20230346928A1

公开(公告)日：2023-11-02

申请号：US18190453

申请日：2023-03-27

申请人： ModernaTX, Inc.

发明人： Joshua P. FREDERICK ,  Susannah HEWITT ,  Ailin BAI ,  Stephen G. HOGE ,  Vladimir PRESNYAK ,  Iain MCFADYEN ,  Kerry BENENATO ,  Ellalahewage Sathyajith KUMARASINGHE

IPC分类号： A61K39/395 ,  C07K14/54 ,  C07K14/705 ,  C07K16/28 ,  A61K39/39 ,  A61K45/06 ,  A61K31/713 ,  A61K48/00 ,  A61K39/00

CPC分类号： A61K39/39558 ,  C07K14/54 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/70532 ,  C07K14/70575 ,  C07K14/70596 ,  C07K16/2818 ,  A61K39/39 ,  A61K45/06 ,  A61K31/713 ,  A61K48/005 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/53 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/32 ,  A61K2039/585 ,  A61K2039/51 ,  A61P35/00

摘要： The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.

公开(公告)号：US20230340404A1

公开(公告)日：2023-10-26

申请号：US18072449

申请日：2022-11-30

申请人： President and Fellows of Harvard College

发明人： Alexander Sing Cheung ,  David J. Mooney

IPC分类号： C12N5/00 ,  A61P35/00 ,  A61K9/00 ,  A61K35/17 ,  A61K38/18 ,  A61K38/19 ,  A61K38/20 ,  A61K39/00 ,  A61K39/395 ,  A61L27/02 ,  A61L27/28 ,  A61L27/38 ,  A61L27/54 ,  A61L27/56 ,  C12N5/0783

CPC分类号： C12N5/0075 ,  A61P35/00 ,  A61K9/0019 ,  A61K35/17 ,  A61K38/1841 ,  A61K38/193 ,  A61K38/2013 ,  A61K39/0011 ,  A61K39/395 ,  A61L27/025 ,  A61L27/28 ,  A61L27/3804 ,  A61L27/54 ,  A61L27/56 ,  C12N5/0638 ,  A61L2300/426 ,  A61L2300/45 ,  C12N2501/15 ,  C12N2501/22 ,  C12N2501/2302 ,  C12N2501/998 ,  C12N2533/00 ,  C12N2533/20

摘要： Embodiments herein described provide antigen-presenting cell-mimetic scaffolds (APC-MS) and use of such scaffolds to manipulating T-cells. More specifically, the scaffolds are useful for promoting growth, division, differentiation, expansion, proliferation, activity, viability, exhaustion, anergy, quiescence, apoptosis, or death of T-cells in various settings, e.g., in vitro, ex vivo, or in vivo. Embodiments described herein further relate to pharmaceutical compositions, kits, and packages containing such scaffolds. Additional embodiments relate to methods for making the scaffolds, compositions, and kits/packages. Also described herein are methods for using the scaffolds, compositions, and/or kits in the diagnosis or therapy of diseases such as cancers, immunodeficiency disorders, and/or autoimmune disorders.

公开(公告)号：US20230338539A1

公开(公告)日：2023-10-26

申请号：US18010483

申请日：2021-06-07

申请人： Immunolight, LLC

发明人： Frederic A. BOURKE, Jr. ,  Harold WALDER ,  Zakaryae FATHI

IPC分类号： A61K41/00 ,  A61K35/13 ,  A61K31/37 ,  A61P35/00 ,  A61K39/00 ,  A61N5/10

CPC分类号： A61K41/0066 ,  A61K35/13 ,  A61K31/37 ,  A61P35/00 ,  A61K39/0011 ,  A61N5/1048 ,  A61K2039/585 ,  A61N2005/1098 ,  A61N2005/1089

摘要： A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.